Pharmaceuticals company Alembic Pharmaceuticals announced Q1FY27 results Consolidated Financial Highlights: Revenue from Operations: Stood at Rs 2,149.77 crore in Q1FY27, representing a growth of 25.66% on a YoY basis compared to Rs 1,710.72 crore in Q1FY26 and an increase of 16.35% on a QoQ basis compared to Rs 1,847.72 crore in Q4FY26. Total Income: For the quarter reached Rs 2,164.70 crore, a 26.06% increase YoY from Rs 1,717.22 crore in Q1FY26 and a 15.56% increase QoQ from Rs 1,873.22 crore in Q4FY26. Profit Before Tax (PBT): Reported at Rs 221.86 crore in Q1FY27, up 16.71% YoY from Rs 190.10 crore in Q1FY26 and an increase of 87.03% QoQ from Rs 118.62 crore in Q4FY26. Net Profit (Profit for the period after non-controlling interests): Stood at Rs 173.07 crore in Q1FY27, reflecting a YoY growth of 12.11% from Rs 154.38 crore in Q1FY26, but a QoQ decrease of 14.62% from Rs 202.70 crore in Q4FY26. Total Comprehensive Income: For the quarter was Rs 174.63 crore, growing 13.15% YoY from Rs 154.33 crore in Q1FY26 and declining 18.04% QoQ from Rs 213.07 crore in Q4FY26. Earnings per Share (EPS): For Q1FY27 was Rs 8.80, compared to Rs 7.85 in Q1FY26 and Rs 10.31 in Q4FY26. Standalone Financial Highlights: Revenue from Operations: Was reported at Rs 1,868.06 crore in Q1FY27, an increase of 25.02% YoY from Rs 1,494.17 crore in Q1FY26 and 8.69% QoQ from Rs 1,718.74 crore in Q4FY26. Total Income: Stood at Rs 1,882.10 crore in Q1FY27, a 25.31% increase YoY from Rs 1,501.96 crore in Q1FY26 and a 7.88% increase QoQ from Rs 1,744.62 crore in Q4FY26. Profit Before Tax (PBT): Reached Rs 255.90 crore in Q1FY27, reflecting a growth of 103.87% YoY from Rs 125.52 crore in Q1FY26 and 47.53% QoQ from Rs 173.46 crore in Q4FY26. Net Profit for the Period: Stood at Rs 196.96 crore in Q1FY27, showing a significant YoY increase of 90.26% from Rs 103.52 crore in Q1FY26, while decreasing 18.97% QoQ from Rs 243.07 crore in Q4FY26. Earnings per Share (EPS): For the standalone entity was Rs 10.02 in Q1FY27, compared to Rs 5.27 in Q1FY26 and Rs 12.37 in Q4FY26. Business Highlights: Segment Performance: The company is exclusively engaged in the "Pharmaceuticals" business, and therefore, it has only one reportable segment. Operating Margin: The consolidated operating margin for Q1FY27 stood at 16.18%, compared to 16.84% in Q1FY26 and 13.84% in Q4FY26. Net Profit Margin: The consolidated net profit margin for Q1FY27 was 8.05%, compared to 9.02% in Q1FY26 and 10.97% in Q4FY26. Exceptional Items: There were no exceptional items reported for Q1FY27. However, for Q4FY26, exceptional items included Rs 6.41 crore relating to employee benefit obligations and Rs 18.35 crore for a write-down on assets of the Sikkim manufacturing facility. Pranav Amin, Managing Director, Alembic Pharmaceuticals, said, “We have started FY27 on a strong note, delivering broad-based growth across our businesses. Performance during the quarter was driven by healthy volume growth, successful new product launches and continued execution across key markets. The US business delivered strong momentum, and the rest of the markets also recorded steady growth. We remain focused on strengthening our product portfolio, advancing our pipeline and driving sustainable long-term growth.” Result PDF